Abstract
Aims: Management of comorbidities represents a critical step in optimal treatment of heart failure (HF) patients. However, minimal attention has been paid whether comorbidity burden and their prognostic value changes over time. Therefore, we examined the association between comorbidities and clinical outcomes in HF patients between 2002 and 2017. Methods and results: The 2002-HF cohort consisted of patients from The Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) trial (n = 1,032). The 2017-HF cohort were outpatient HF patients enrolled after hospitalization for HF in a tertiary referral academic hospital (n = 382). Kaplan meier and cox regression analyses were used to assess the association of comorbidities with HF hospitalization and all-cause mortality. Patients from the 2017-cohort were more likely to be classified as HF with preserved ejection fraction (24 vs 15%, p < 0.001), compared to patients from the 2002-cohort. Comorbidity burden was comparable between both cohorts (mean of 3.9 comorbidities per patient) and substantially increased with age. Higher comorbidity burden was significantly associated with a comparable increased risk for HF hospitalization and all-cause mortality (HR 1.12 [1.02–1.22] and HR 1.18 [1.05–1.32]), in the 2002- and 2017-cohort respectively. When assessing individual comorbidities, obesity yielded a statistically higher prognostic effect on outcome in the 2017-cohort compared to the 2002-HF cohort (p for interaction 0.026). Conclusion: Despite major advances in HF treatment over the past decades, comorbidity burden remains high in HF and influences outcome to a large extent. Obesity emerges as a prominent comorbidity, and efforts should be made for prevention and treatment. Graphical abstract: Created with BioRender.com. [Figure not available: see fulltext.]
Original language | English |
---|---|
Pages (from-to) | 123-133 |
Number of pages | 11 |
Journal | Clinical Research in Cardiology |
Volume | 112 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2023 |
Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by grants from the Dutch Heart Foundation (CVON SHE-PREDICTS-HF, Grant 2017-21; CVON RED-CVD, Grant 2017-11; CVON PREDICT2, grant 2018-30; CVON DOUBLE DOSE, grant 2020B005; and grant 2000Z003), by a grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)), and by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr. Meijers is supported by the Mandema-Stipendium of the Junior Scientific Masterclass 2020-10 of the University Medical Center Groningen and by the Dutch Heart Foundation (Dekker grant 03-005-2021-T005). The funders had no role in the design and conduct of the study; collection, analysis, and interpretation of data; writing of the manuscript; and decision to submit the manuscript for publication.
Publisher Copyright:
© 2022, The Author(s).